📰 Hematology Development News
Page 2 - Hematology Development News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Hematology Development. Real-time updates on events, politics, business and more.
May 2, 2023
The treatment showed significant improvement in patients in patients who require frequent blood transfusions and are at risk of infection.
May 1, 2023
Applications based on results from Phase 3 COMMANDS study in which first-in-class Reblozyl demonstrated a highly statistically significant and clinically meaningful improvement compared to an... | May 1, 2023
May 1, 2023
Applications based on results from Phase 3 COMMANDS study in which first-in-class Reblozyl demonstrated a highly statistically significant and clinically meaningful improvement compared to an erythropoiesis-stimulating agent in patients with very low/low/intermediate-risk MDSU.S. FDA has assigned a target action dat...
May 1, 2023
The FDA has granted a priority review to the supplemental biologics license application seeking to expand the current indication of luspatercep to include treatment of anemia in patients with very low- to intermediate-risk myelodysplastic syndrome who have not previously received erythropoiesis-stimulating agents and who may require red blood cell transfusions.
March 3, 2023
Third authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with diseases impacted by anemia Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission
November 22, 2022
First data to be presented as a late-breaker abstract from global pivotal APPLY-PNH trial of investigational oral monotherapy iptacopan in paroxysmal nocturnal hemoglobinaria (PNH), a rare and
November 22, 2022
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH
November 22, 2022
First data to be presented as a late-breaker abstract from global pivotal APPLY-PNH trial of investigational oral monotherapy iptacopan in paroxys...
August 30, 2022
Overall survival results from pooled exploratory analysis of MONALEESA trials in patients with aggressive HR+/HER2- advanced breast cancer treated with Kisqali Data from VISION study reporting associations
August 15, 2022
15.08.2022 - Phase III CANOPY-A trial did not meet primary endpoint of disease-free survival in patients with stages II-IIIA and IIIB completely resected non-small cell lung cancer1Findings will be presented at an upcoming medical meetingNovartis remains ... Seite 1